Analyse de l'application Medeligo pour le 16 mai

Medeligo® provides instant access to the latest oncology literature and information for treatment, procedure, testing, and management information across all oncology subspecialties. FINGERTIP ACCESS TO THE LATEST ONCOLOGY INFORMATION - AI-powered search engineered by technologists and medical librarians - Effortless UI gets to answers in seconds - Covers more than 2,000 solid tumors and cancers, including the WHO Classification of Tumours - Real-time searches provide the latest information available - Searches only the most trusted medical journals, databases, and information resources - Primary source material: unfiltered, unbiased, uncurated Benefits include: - Find and read the latest oncology literature in seconds - Watch relevant videos and browse images - Prepare for patient rounds, consults, and surgeries - Answer patient-specific questions quickly at tumor boards - Share, print, or save articles Limited introductory price of $49.99 (Reg. $149.99) for the All Access (1 year) subscription — includes a risk-free 3-month trial. To learn more, please visit www.medeligo.com. After the free trial period, your subscription will continue for $49.99/year, and your iTunes account will be charged. If you do not wish to continue your subscription after your free trial ends, turn off auto-renew in your Account Settings 24 hours before the end of your free trial. Subscriptions will automatically renew when they expire unless you turn off auto-renew at least 24 hours before the end of your subscription period. Your account will be charged $49.99 for renewal within 24 hours before the end of your subscription period. You can manage your subscription and turn off auto-renew by going to your Account Settings. Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable. You can read more about our terms and conditions here: Privacy policy: http://medeligo.com/privacy-policy/ Terms of service: http://medeligo.com/terms-of-service/